Life Sciences Archive » June, 2026

Life Sciences - June, 2026

274 articles

• Smoke Shops Take Aim At Mass. Ban On Vapes And Pouches
• AIDS Group Says Cigna-Owned Express Scripts Hurts Patients
• Zenas Wins Dismissal Of IPO Suit Over R&D Spending Claims
• Cellspin Settles Challenges To Its Patents At PTAB
• Pharma Co. Seeks Injunction Over Chinese Military Co. Label
• Cigna, Others Fight Ohio AG's Drug Price-Fixing Suit
• ResMed Gets PTAB To Ax 1 Out Of 2 Sleep Apnea Patents
• Investor Sues In Chancery Over Alleged Sham Freeze-Out
• Key Tips For Patenting Antibody-Drug Conjugate Inventions
• $885M IBS Drug Verdict Tests Pay-For-Delay Limits
• ITC Opens Patent Probe Into Chinese Protein Testing Co.
• High Court Sends 3 Roundup Cases Back After Monsanto Win
• Power To The Paralegals: Burnout As A Structural Problem
• Wash. Panel Revives Claims Over Fertility Operation Injury
• 26 States Sue To Nix Medicaid Work Rule For Medically Frail
• AstraZeneca To Pay $34M In Texas Kickbacks Settlement
• Hospital That Halted Gender Care Must Show Cause
• Sanofi Must Face Labeling Claims In Taxotere Eye Injury MDL
• Insulin Makers Can't Nix 340B Antitrust Claims On Remand
• Juvederm Users Say AbbVie Hid Risks Of Filler
• Ex-Sales Director Says Fortive Unit Used RIF To Mask Firing
• PBMs Drop Fight To Pause Insulin Case Amid Deal Talks
• Class Actions At The Circuit Courts: June Lessons
• Takeaways From 1st Del. Ruling Applying Moelis Amendments
• Asthma Drug Developer To Wind Down In Chancery Court
• Ill. Law Firm MSO Bill Clashes With Court Power, Ethics Rules
• Supreme Court Shuts Down 4 Patent Cases
• 4 Takeaways From The High Court's Monsanto Ruling
• PACER Fees Will Rise To Fund Cyber Defense Upgrades
• Pfizer Beats Ex-Worker's Whistleblower Retaliation Suit
• Endoscopy Device Maker's Trade Secret Suit Trimmed In Ohio
• DC Circ. Affirms FDA Can Block Norwich's IBS Generic
• EU Probing Sanofi For Disparaging Rival Flu Vaccine
• DEA Will Back Cannabis' Medical Utility In Historic Hearing
• The Future Of WDTX Patent Litigation After Judge Albright
• ITC Votes To Tee Up Duties For Korean Chemical Imports
• Taxation With Representation: Sidley, Paul Weiss, Kirkland
• REIT Execs Hid Queens Megacampus Woes, Suit Says
• Don't Miss It: Sidley, Cooley Steer Hot Deals
• State Courts Must Be Gatekeepers Of Expert Testimony
• Sandoz Still Can't Escape Generics Claims From GM, Others
• Robo-Surgery Co., FTC Urge 9th Circ. To Revive Antitrust Case
• Meta Fails To Knock Out BIPA Voiceprint Privacy Claims
• Texas Faces Tough Questions In Tylenol Autism Appeal
• Anti-Pot Advocates Preview Arguments In DEA Hearings
• Novo Nordisk Gets 401(k) Investment Suit Narrowed
• 5 Key Factors Behind USPTO's Inter Partes Review Decisions
• No Immunity In Idaho THC Child Abuse Registry Suit
• Moshing Makes Me A Better Lawyer
• Sidley Grows In Calif. With Life Sciences, Emerging Cos. Hires
• High Court Ruling Casts Doubt On Status-Based Gun Bans
• 4th Circ. Says Supply Co.'s Foreign Member Kills Diversity
• 2 Firms Lead Merck's $11.3B Bio-Techne Life Sciences Deal
• Monsanto Wins High Court Fight Over Roundup Cancer Warnings
• NY Judge Halts DOJ Bid For Trans Youth Medical Records
• Wholesalers Say Novo Can't Duck GLP-1 Antitrust Suits
• Florida AG Opens Probe Over CVS' Ownership Of Caremark
• Pfizer Defeats Generic Drug Claims From State AGs
• Gene Therapy Co. Sangamo Gets Initial OK For $30M DIP
• Why Highly Specialized Experts May Risk Exclusion At Trial
• Generic Drugs Do Not Reach Patients Sooner In The EU
• A Midyear Look At Antiterrorism Act Jurisprudence And Policy
• Texas Woman Says ERs Violated EMTALA Amid Miscarriage
• FTC Tells 4th Circ. Court Got It Wrong In J&J Stelara Case
• No Slowdown: A Midyear Look At FDA Ad Enforcement
• Stryker Says Data Breach Suit Built On Speculation
• Green Group Wants Records Behind Trump's Weed Killer Order
• FTC's Clinical Trial Requirement Threatens Food Claim Rules
• BioNTech Accused Of Firing Nurse Over Drug Trial Concerns
• Feds Tout AI's Role In $6.5B Healthcare Fraud Crackdown
• Fed. Circ. Backs Pfizer Win In Paxlovid Patent Dispute
• Drawing A Line Between Settlement Pressure And Extortion
• Gene Therapy Developer Sangamo Hits Ch. 11 With Sale Plans
• Can Unread Emails Trigger Arbitration? 9th Circ. Airs Doubts
• Cassava Investors Ink $31M Drug Suit Deal Alongside Appeal
• Zymergen Investors Get First OK For $125M Settlement
• FTC Requires Fix For Aurobindo's $250M Lannett Deal
• No Trial For Splenda Maker, Scientist In Defamation Suit
• Sorrento RICO Case Naming Jackson Walker Gets Axed
• NORML Fights Exclusion From DEA Pot Rescheduling Hearing
• Yale Health Escapes Trade Law Claim In Insemination Suit
• 3rd Circ. Backs Quest Over Claims Of Bad 401(k) Management
• Holland & Knight Adds Jones Day Atty To Atlanta, DC Teams
• USTR Launches Probe Into German Pharma Costs
• Gov't Says It Should Face Vax IP Claims, Not Moderna
• Justices Seek Solicitor General's Views On Drug Pricing Law
• Paul Weiss, Kirkland Steer $10.9B AbbVie, Apogee Deal
• Eli Lilly Weight Drug TM Deal Too Secretive, Ind. Judge Says
• Express Scripts Can't Ditch Meta Wiretap Suit Yet
• Fertility Chain Beats Suit Alleging Bogus Embryo Test Claims
• Novo Nordisk Sued Over Data Hack Tied To Extortionist Group
• Once Dominated By Patent Claims, IP Suits Now More Diverse
• Full Fed. Circ. Skips DePuy Bid To Redo Spine Patent Dispute
• RFK Jr. Urges 1st Circ. To Reinstate His Vaccine Advisers
• DEA Picks Only Pot Foes To Join Rescheduling Hearings
• Cannabis World Cheers Justices' Gun Rights Ruling
• Goodwin, Latham Lead Biotech Kardigan's $400M IPO
• Gibson Dunn Hires Ropes & Gray Health Regulatory Atty In DC
• Patent Claims On Novartis Unit Drug Invalid, Del. Judge Says
• Founding An Autism Academy Made Me A Better Lawyer
• Pharma Co. Says Machine Breakdown Triggered Coverage
• High Court Bars Federal Review Of State Court Appeals
• Justices Allow Gun Rights For Marijuana User
• Eli Lilly Urges Full Fed. Circ. To Scrap Teva's $177M IP Win
• Hikma Ruling Raises Patent Pleading Bar Beyond Drug Cases
• Grocery Chain Says Aon Put $40M In Opioid Coverage At Risk
• Sen. Committee Clears Drug Disclosure, Biosimilar Bills
• ITC, Masimo Tell Full Fed. Circ. To Skip Apple Watch Review
• Embecta Investor Suit Says Pen Needle Weakness Was Hidden
• Del. Court Invalidates Patent Claims In Bioscience Co. Row
• Fed. Circ. Affirms No Block On Stryker Spine Device In IP Fight
• Glenmark Pharma Beats Suit Over Recalled Cholesterol Drugs
• Syngenta, Chevron Bids To Move Paraquat Cases Opposed
• HHS Urges DC Court To Toss AbbVie 340B Audit Challenge
• Rule Of Law Requires Gov't Engagement With Bar, Not Retreat
• Sanofi Sued Over Qunol CoQ10 'Superior Absorption' Claims
• Eli Lilly Settles Mounjaro TM Suit Against Seattle Area Clinics
• Del. Judge Won't Touch Jury's $83M Diagnostics IP Verdict
• SEC Settles Insider Trading Suit Against Biotech Investor
• Cigna Loses Privilege Bid Due To 'Inaccurate, Redundant' Log
• Judge Allows Pfizer, Moderna Defenses In GSK Vax IP Dispute
• J&J Talc Trial In LA Ends With Deadlocked Jury
• Md. Judge Continues Health Case Law Streak With ACA Ruling
• AG Watch: Oregon's Strategic Civil Enforcement Approach
• How Nasdaq's 23/5 Rule Will Alter Public Offering Strategies
• Pfizer Agrees To Deal To End Depo-Provera MDL
• The Paradoxical Duty To Adopt AI When You Can't Bill For It
• DOJ Says NY Court Can't Block Texas Trans Records Probe
• Squires Rejects 7 AIA Cases, Explains Earlier Tesla Decision
• Univ. Of Washington Beats Medical Prof's Bias Suit At Trial
• FTC Pulls OptumRx Insulin Price Case To Review Final Deal
• $239M LabCorp Deal Illegally Shared Genetic Info, Suit Says
• CareFirst Says Intent Standard Was Misread In Stelara Case
• Mead Johnson Wins New Trial Over $60M NEC Formula Verdict
• Wyo. Judge Nixes 3 Abortion Care Limits As Unconstitutional
• Nano-X Investors Sue Over Korea Plant Restructuring Hit
• Hagens Berman Must Cover Fees After Misconduct Findings
• Mylan Investor Claims Atty Fees Too Much For 'Lost' Case
• Judge Gives First OK To $69M ChemoCentryx Deal
• Jury Tells Amgen To Pay $20.2M In Antibody Patent Trial
• J&J Trial Over Doctor's Cancer Death Ends In Settlement
• Disability Rights Orgs. Seek To Halt NY, Ill. 'Aid-In-Dying' Laws
• Zoetis Brass Face Derivative Suit Over Pet Meds Statements
• Insider Trading Defense May Draw On 'Varsity Blues' Playbook
• Ex-Honeywell China GC Can't Bring US Bias Suit, Judge Says
• Taxation With Representation: Gibson Dunn, Davis Polk, S&C
• AbbVie Loses Colorado 340B Drug Pricing Law Challenge
• Ex-Pharma Exec Fights SEC 'Shadow Trading' Win At 9th Circ.
• 11th Circ. Seeks Fla., Ga. Justices' Input On Opioid Coverage
• Stop & Shop Parent Pays $40M On Inflated Drug Price Claims
• Chinese Biopharma Sues Over National Security Threat Label
• 23andMe To Pay $46.7M To Resolve Data Breach Claims
• Tips For Litigating Life Sciences Investigations At The ITC
• Ch. 15 Ruling Is A Restructuring Blueprint For Cannabis Cos.
• Unsecured Synthetic Royalties May Be Returning
• Cancer Diagnostics Firm Ignite Inks $150M SPAC Merger
• Moderna Says New COVID Vax Doesn't Infringe BioNTech IP
• 7th Circ. Rejects Firms' Bid For More Flea Collar MDL Fees
• Cow Horse Makes Me A Better Lawyer
• DexCom Says Diabetes Tech Issue Isn't Investor Fraud
• Catalyst Investor Sues Over Proposed $4.1B Angelini Buyout
• FDA Rule For Nicotine Pouches Likely Flawed, Judge Says
• PTAB Invalidates Inari Embolism Treatment Patent
• Greenberg Traurig Hires 2 IP Litigators From Goodwin Procter
• Alachua Wants DOD's $147M Chapter 11 Claim Slashed To $5M
• Abbott Offered Faulty Health Plan Option, Ex-Worker Says
• J&J Hit With $32M Verdict In LA Baby Powder Cancer Trial
• AmeriHealth Unit, PBM Look To Escape Pharmacy Fee Suit
• DC Circ. Asked To Freeze DOJ's Medical Pot Rescheduling
• Protecting AI-Driven Innovation In Life Sciences IP
• Amgen Can't Amend Petition To Address Potential Double Tax
• $25M Patent Verdict Against Ferring Backed By Del. Court
• Goodwin, Covington Lead Parabilis' $670M Upsized IPO
• What Prop 65 Listings For Welding Fumes, Drugs Mean For Cos.
• Insurance Cos. Score Dismissal Of Zepbound Coverage Case
• Lab To Pay $4.9M To Settle AGs' COVID Test Pricing Suit
• Acadia Pharma Must Face Investors' Drug Approval Claims
• Conn. Woman Says Pharmacy 'Grossly' Exceeded Med Dose
• Novartis, AbbVie Lose Bid To Halt Wash. 340B Pharmacy Law
• Morrison Foerster Brings On Sidley Patent Litigation Duo
• Agensys Sues Biopharmas For Alleged Trade Secret Theft
• Fed. Circ. 'Recalibrates' Analysis For Constitutional Standing
• 4th Circ. Revives Ex-Gilead Worker's Defamation Suit
• Eli Lilly Wins Order Halting Alleged Trulicity Fraud
• McKesson, Rite Aid Trust Clash Over Ch. 11 Claims Transfer
• High Court's Hikma Decision Reshapes 'Skinny Label' Suits
• Virginia's Cannabis Retail Veto Leaves Industry In Legal Limbo
• BioTech Co. Hit Investor Suit Over Cancer Test Trial Miss
• Biopharma Founder's Nonsolicit Clause Void Under Calif. Law
• Ex-Zydus Unit Exec Alleges 'Second-Class Citizen' Treatment
• Novanta Buys Riverpoint In $1.45B Deal Steered By 3 Firms
• 4th Circ. Lets Hartford Unit Off The Hook For Drug Test Fight
• The Law360 400: A Look At The Top 100 Firms
• Checking For AI Errors Is Now A Two-Way Street
• Davis Polk, Slaughter & May Steer GSK's $10.6B Nuvalent Deal
• Fed. Circ. Scrutinizes UT's 'Inflammatory' Comments In IP Trial
• Eli Lilly Conspiracy Claim In Compound Drug Row Challenged
• AIPLA, NAM Rally Behind Moderna's Fight Over Vax Patents
• Fed. Circ. Panel Backs Invalidation Of OxyContin Patent
• Biogen To End Investors' Alzheimer's Drug Case For $18.9M
• Goodwin, Fenwick Guide Incyte-Vega Deal Worth Up To $2B
• Class Attys Want $11.6M In Fees From $35M Teva Inhaler Deal
• Johnson & Johnson Paying $1B For Oncology Startup Firefly
• Sleep Aid Buyers Say 'Non-Habit' Pills Can Cause Dependence
• Ex-Trader Accused Of Profiting From Cousin's Insider Info
• JPML Denies Industrywide Spinal Device Injury MDL Bid
• Trans Patients Urge Blocking DOJ 'Campaign Of Harassment'
• J&J Cleared Of Talc Liability In LA Bellwether Trial
• IRhythm Inks $45M Deal With Investors In Heart Device Suit
• Fed. Circ. Backs Melinta Patent Win In Injections Case
• Sanofi Eczema Drug Suits Consolidated, Sent To NJ Fed Court
• CMS Hemp Program Foes Take Standing Fight To DC Circ.
• Health Funds Ink $5.5M Generic Drug Deal With Breckenridge
• The Biz Court Digest: Shoring Up Corporate Law In Maryland
• Don't Miss It: Hogan Lovells, Cooley Steer Hot Deals
• State Enviro Agencies Give Cosmetics Regulation A Makeover
• FDA's Chemical Review Process Heats Up Food Industry Risk
• UK Litigation Roundup: Here's What You Missed In London
• No 'Conspiracy To Hide Asbestos' In Talc, J&J Atty Tells Jury
• Generics Cos. Get More Freedom In High Court Patent Ruling
• Amgen Won't Face 'Nonsensical' Rodent Antibody IP At Trial
• Eli Lilly's 'Overbroad' Weight Drug TM Deal Rejected
• Doctor Lied About Risky 'Basket Weave' Surgery, Patients Say
• Legislative Update: Cannabis And Psychedelics Bill Roundup
• Fed. Circ. Invalidates Spinal Implant Patent Claims
• Judge Questions Fees In Abbott Investors' $40M Formula Deal
• Inotiv Gets Cash Access To Pursue Ch. 11 Prepack Track
• Catalent Investors Say No Objections To $78M Deal, Fee Bid
• US Middle Market PE Surge Expected After Strong 2025
• Competing At Poker Makes Me A Better Lawyer
• Supreme Court Shuts Down 'Skinny Label' Drug Patent Suit
• AbbVie Loses Miss. Discount Drug Law Challenge For Good
• Medtronic Unit Must Face Bellwether Hernia Mesh Claims
• Balwani Takes Theranos Conviction Challenge To Justices
• 'This Is Their Document': Jury Told J&J Docs Prove Talc Lies
• Squires Institutes 3 Patent Reviews, Denies 3 Others
• Why IPR Slowdown Has Not Led To More Patent Litigation
• Ill. Court Blocks Fla. Suit Targeting Gender Care Policies
• Trans Youth Sue NYU Langone, DOJ To Bar Records Release
• Purdue Pharma Heir Sues Son Over Sackler Matriarch's Estate
• 5 Things Associates Must Ask About Their Firm's Merger Plan
• BigLaw Insider Trading Defendants Have Big-Name Legal Help
• Brain Computer Interfaces Boot Up Multipronged Legal Issues
• 1st Circ. Panel Seems Poised To Uphold RI Drug Pricing Law
• Supplier Can't Force Arbitration Of Worker's Wage Suit
• IVF Patients Say Natera Profited Off Ineffective Embryo Tests
• Drug Research Co. Inotiv Files Ch. 11 To Cut $325M In Debt
• Paul Weiss Hires Deals Pro From Dechert In NY
• Talc Tester Says J&J Never Pressured Him To Hide Asbestos
• Generics Makers Tell 3rd Circ. Buyers Too Few For Class
• FTC Sues Supplement Co. Over Mental Health, Income Claims
• DLA Piper Brings On A&O Shearman M&A Partner In SF
• Turning To The Courts When PBM Reform Falls Short
• 2 'Rocket Dockets' And The Rules That Propel Them
• Pharma Co. Inks $7M Deal To End Investor's Cancer Study Suit
• Judge Ends Nausea Drug Suit After Invalidating Other Patents
• Lack Of Indemnity Liability Doomed Vax IP Case, Judge Says
• Chinese Protein Testing Tech Infringes US Patents, Co. Says
• 3rd Circ. Preview: AI Copyright Spat, NJ Gun Law Battle
• Albertsons Had Duty To Curb Opioid Diversion, Judge Rules
• Justices Say 11th Circ. Wrong To Consider Posttrial DNA Test
• 'We Wouldn't Be Alive' If Talc Could Reach Ovaries, Jury Told
• Valeant Investors Should Get Cert. In PwC Fight, Report Says
• 11th Circ. Won't Stop Joint Hearing In Depo-Provera MDL
• Moderna Tells Fed. Circ. US Must Face COVID Vax Patent Case
• Garmin's Smart Scale Uses Estimates In Readings, Suit Says
• Judge Trims Dental Patent Case, But Keeps Patent Alive
• Plaintiffs' Counsel In Tylenol MDL Agree To $50K Donation
• Calif. Ruling Lowers Bar For Health Data Breach Claims
• NC Biz Court Bulletin: Referee Tapped, CEO To Be Deposed
• US Trade Officials Open IP Probe Into Vietnam
• La. Sends Psychedelic Therapy Research Bill To Governor
• Catching Up With Delaware's Chancery Court
• Justices Skip CareDx's Bid To Revive $45M False Ad Award